NDA 017707 · Ge Healthcare
Mpi Indium Dtpa In 111
Indium In-111 Pentetate Disodium · Intrathecal · Radioactive Diagnostic Agent
NovelLast checked: Nov 19, 2026Latest source record: Dec 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Feb 18, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
0 Phase 3, 1 recruiting
FAERS reports
14
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 10, 2024.
INDICATIONS AND USAGE Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 18, 1982 Original approval · Type 1 - New Molecular Entity
1 products under this application
- MPI INDIUM DTPA IN 111 · INDIUM IN-111 PENTETATE DISODIUM 1mCi/ML · INJECTABLE, INTRATHECAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Indium In-111 Pentetate Disodium" as an intervention, any sponsor and status, largest first.
- Advanced Diffusion Imaging in Renal Cancer PatientsActive, not recruiting
NYU Langone HealthAcademic, hospital or other
NCT06116253 · 39 participants · Start Dec 1, 2022 · Primary completion Dec 1, 2028
Drug: Tc-99m Pentetate · For: Renal Cancer
Sites: New York, New York
Mayo ClinicAcademic, hospital or other
NCT07817706 · 20 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2027
Drug: Mannitol Solution 76 mOsm/L; Mannitol Solution 189 mOsm/L and 1 more · For: Disorders of Gut Brain Interaction
Sites: Rochester, Minnesota
University of WashingtonAcademic, hospital or other
NCT01982123 · 12 participants · Start Jan 17, 2014 · Primary completion Sep 13, 2017
Drug: Technetium Tc-99m DTPA · For: Lung Carcinoma; Malignant Neoplasm
Sites: Seattle, Washington · 2 sites in all
- Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's LymphomaTerminated
National Cancer Institute (NCI)NIH
NCT01468311 · 6 participants · Start Oct 11, 2011 · Primary completion Nov 16, 2014
Drug: BEAM · For: Hodgkin Disease; Hodgkin Lymphoma
Sites: Bethesda, Maryland
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00477503 · 1 participants · Start May 2007 · Primary completion Jul 2009
Drug: Gallium-67 Citrate (Ga-67); In-111 DTPA (In-111 pentetate) · For: Central Nervous System Tumors; Brain Tumors
Sites: Houston, Texas
- Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition DiseaseTerminated
University of North Carolina, Chapel HillAcademic, hospital or other
NCT02947022 · 1 participants · Start Oct 2016 · Primary completion Jan 31, 2017
Drug: Calcium DTPA; Zinc DTPA · For: Headache; Cognitive Disturbance; Skin Hyperpigmentation and 1 more
Sites: Chapel Hill, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event13
- drug ineffective8
- radioisotope scan abnormal3
- false positive investigation result2
- meningitis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2023 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.